GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data ...

Columnist Sam Kirton finds that filling the silence is part of living with a chronic condition, especially amid retirement and COVID-19.

Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic ...

Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.

Columnist Sam Kirton describes how daunting an IPF prognosis can be — but also how things are looking up for patients today.

IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.

A flash flood can pose unique risks for PF patients, says columnist Sam Kirton, who shares several ways to prepare for such an emergency.

Looking for information on Shallow Breathing (Tachypnea) in pulmonary fibrosis? Read about breathing alterations in IPF here.

Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.